The evolving biology and treatment of prostate cancer
J. Clin. Invest. Russel S. Taichman, et al. 117:2351 doi:10.1172/JCI31791 [
Go to this article.]
Figure 3Histologic changes associated with prostate tumorigenesis. For more information, see refs.
21–
34. PIA, proliferative inflammatory atrophy;
RNASEL, 2′-5′-oligoadenylate–dependent RNase L;
AMACR, α-methylacyl-coenzyme A racemase;
EZH2, enhancer of zeste homolog 2; PcG, polycomb group. Original magnification, ×100.
